Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Professor Awarded $5.6 Million NIH Grant to Develop Therapeutics Against Deadly Viruses

24.06.2008
Researchers at the Uniformed Services University of the Health Sciences (USU) have been awarded a $5.6 million grant from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to develop and test vaccines and treatments for the Nipah and Hendra viruses.

Dr. Christopher C. Broder, USU professor of microbiology and immunology and director of the university’s interdisciplinary program in Emerging Infectious Diseases, is the principal investigator of the grant from NIAID. The grant was awarded to further develop the vaccines and therapeutics for Nipah and Hendra that his group has been working on for the past several years.

The award will support a continued collaboration with investigators Lin-Fa Wang, Ph.D. and Deborah Middleton M.V.Sc, Ph.D. of Australia’s Commonwealth Scientific and Industrial Research Organization (CSIRO) Livestock Industries, Australian Animal Health Laboratory (AAHL) and Australian Biosecurity Cooperative Research Center (AB-CRC) in Geelong, Victoria, where there is a high-level biosafety and security facility for testing the vaccines and therapeutics against these deadly viruses in appropriate models.

Hendra virus and Nipah virus are recently emerged paramyxoviruses that are highly pathogenic and can cause lethal infections in several animals and in humans. Since their initial discovery in Australia and Malaysia, sporadic Hendra outbreaks have been reported from 1995 to 2007, while Nipah has caused at least 9 outbreaks between 1998 and 2008. The majority of these episodes have occurred on a regular basis in Bangladesh and India, with human case fatality rates approaching 75% along with evidence of human-to-human transmission. The most recent appearance of Nipah in 2008 claimed the lives of several children. Studies have demonstrated that the natural reservoirs for Hendra and Nipah viruses are bats, primarily several different species of large fruit bats commonly referred to as flying foxes.

... more about:
»Hendra »NIH »Nipah »Vaccine »therapeutic

The first steps in countering infections caused by these viruses were to develop a vaccine that was both safe and effective, and also to find antibodies that could neutralize them. In earlier work, also supported by NIAID through the Middle-Atlantic Regional Center of Excellence for Biodefense and Emerging Infectious Diseases Research (MARCE), a subunit vaccine for Nipah and Hendra, composed of a piece of the virus known as the G glycoprotein, was developed by Dr. Katharine Bossart, a former graduate student of Broder’s laboratory. Recent experiments by Dr. Bossart and colleagues have shown the vaccine to be very effective in preventing Nipah virus disease.

Antibodies on the other hand are proteins that are found in blood or other bodily fluids of animals and humans that are used by the immune system to identify and neutralize foreign molecules, including bacteria and viruses.

The neutralization of an invading virus is the process by which an antibody can specifically bind and block its infection, and in other recent MARCE-supported studies carried out by Broder’s group in collaboration with Dimiter S. Dimitrov, Ph.D., of the National Cancer Institute’s, Center for Cancer Research in Frederick, Md., and Zhongyu Zhu, Ph.D., of Dimitrov's group, a very potent Nipah and Hendra virus neutralizing human monoclonal antibody (m102.4) was developed as a potential therapeutic that could be administered to people infected by these viruses.

“We now have the critical resources needed to evaluate the therapeutic potential of both vaccines and perhaps more importantly a potent human antibody against both Nipah virus and Hendra virus, that could help control outbreaks in geographical regions susceptible to these emerging viruses, and result in a real benefit to those people at risk of infection and disease caused by these deadly agents," said Broder. “Our success in obtaining these new critical funds is also evidence of the success of NIAID’s Regional Center of Excellence program,” Broder added.

This NIH award will also support and bring together the expertise to structurally characterize the interaction between the Nipah and Hendra virus and the receptor proteins on cells that serve the gateway for virus infection, led by Dimitar B. Nikolov, Ph.D., and Kai Xu of Nikolov’s team at the Structural Biology Program of the Memorial Sloan-Kettering Cancer Center, in New York. Information from these additional studies may lead to the discovery of new therapeutics targeting the virus-host cell infection process.

NIAID supports basic and applied research to prevent, diagnose and treat infectious diseases, influenza, tuberculosis, malaria and illness from potential agents of bioterrorism. It also supports research on basic immunology, transplantation and immune-related disorders, including autoimmune diseases, asthma and allergies.

Located on the grounds of Bethesda’s National Naval Medical Center and across from the National Institutes of Health, USU is the nation’s federal school of medicine and graduate school of nursing, and also offers several graduate programs in the biomedical sciences and public health. The university educates health care professionals dedicated to career service in the Department of Defense and the U.S. Public Health Service. Medical students are active-duty uniformed officers in the Army, Navy, Air Force and Public Health Service, who are being educated to deal with wartime casualties, natural disasters, emerging infectious diseases, and other public health emergencies. Of the university’s more than 4,000 physician alumni, the vast majority serve on active duty and are supporting operations in Iraq, Afghanistan, and elsewhere, offering their leadership and expertise.

Office of External Affairs | newswise
Further information:
http://www.usuhs.mil

Further reports about: Hendra NIH Nipah Vaccine therapeutic

More articles from Life Sciences:

nachricht The hidden structure of the periodic system
17.06.2019 | Max-Planck-Institut für Mathematik in den Naturwissenschaften (MPIMIS)

nachricht Tiny probe that senses deep in the lung set to shed light on disease
17.06.2019 | University of Edinburgh

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: The hidden structure of the periodic system

The well-known representation of chemical elements is just one example of how objects can be arranged and classified

The periodic table of elements that most chemistry books depict is only one special case. This tabular overview of the chemical elements, which goes back to...

Im Focus: MPSD team discovers light-induced ferroelectricity in strontium titanate

Light can be used not only to measure materials’ properties, but also to change them. Especially interesting are those cases in which the function of a material can be modified, such as its ability to conduct electricity or to store information in its magnetic state. A team led by Andrea Cavalleri from the Max Planck Institute for the Structure and Dynamics of Matter in Hamburg used terahertz frequency light pulses to transform a non-ferroelectric material into a ferroelectric one.

Ferroelectricity is a state in which the constituent lattice “looks” in one specific direction, forming a macroscopic electrical polarisation. The ability to...

Im Focus: Determining the Earth’s gravity field more accurately than ever before

Researchers at TU Graz calculate the most accurate gravity field determination of the Earth using 1.16 billion satellite measurements. This yields valuable knowledge for climate research.

The Earth’s gravity fluctuates from place to place. Geodesists use this phenomenon to observe geodynamic and climatological processes. Using...

Im Focus: Tube anemone has the largest animal mitochondrial genome ever sequenced

Discovery by Brazilian and US researchers could change the classification of two species, which appear more akin to jellyfish than was thought.

The tube anemone Isarachnanthus nocturnus is only 15 cm long but has the largest mitochondrial genome of any animal sequenced to date, with 80,923 base pairs....

Im Focus: Tiny light box opens new doors into the nanoworld

Researchers at Chalmers University of Technology, Sweden, have discovered a completely new way of capturing, amplifying and linking light to matter at the nanolevel. Using a tiny box, built from stacked atomically thin material, they have succeeded in creating a type of feedback loop in which light and matter become one. The discovery, which was recently published in Nature Nanotechnology, opens up new possibilities in the world of nanophotonics.

Photonics is concerned with various means of using light. Fibre-optic communication is an example of photonics, as is the technology behind photodetectors and...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

SEMANTiCS 2019 brings together industry leaders and data scientists in Karlsruhe

29.04.2019 | Event News

Revered mathematicians and computer scientists converge with 200 young researchers in Heidelberg!

17.04.2019 | Event News

First dust conference in the Central Asian part of the earth’s dust belt

15.04.2019 | Event News

 
Latest News

Novel communications architecture for future ultra-high speed wireless networks

17.06.2019 | Information Technology

Climate Change in West Africa

17.06.2019 | Earth Sciences

Robotic fish to replace animal testing

17.06.2019 | Ecology, The Environment and Conservation

VideoLinks
Science & Research
Overview of more VideoLinks >>>